BR9714739A - Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu - Google Patents

Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu

Info

Publication number
BR9714739A
BR9714739A BR9714739-7A BR9714739A BR9714739A BR 9714739 A BR9714739 A BR 9714739A BR 9714739 A BR9714739 A BR 9714739A BR 9714739 A BR9714739 A BR 9714739A
Authority
BR
Brazil
Prior art keywords
respiratory depression
agonist
delta
pharmaceutical composition
side effects
Prior art date
Application number
BR9714739-7A
Other languages
English (en)
Inventor
Kwen-Jen Chang
Robert W Mcnutt Jr
Hugh O Pettit
Michael J Bishop
Original Assignee
Delta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Pharmaceuticals Inc filed Critical Delta Pharmaceuticals Inc
Publication of BR9714739A publication Critical patent/BR9714739A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B>COMPOSIçãO FARMACêUTICA PARA REDUZIR A DEPRESSãO RESPIRATóRIA E OS EFEITOS COLATERAIS INERENTES DE COMPOSTOS OPIóIDES MU<D> Um método para reduzir, tratar ou prevenir a depressão respiratória mediada por droga, rigidez muscular, ou náusea/vómito em um animal. O método compreende a administração de um agonista de opióide mu/delta misturado ou uma droga para mediar a depressão respiratória do animal, incluindo a administração, ao animal que recebe a droga, de uma quantidade eficaz de um composto agonista receptor delta. A figura mostra o efeito de isómero positivo do agonista delta BW73U86 sobre analgesia e depressão respiratória induzida pelo agonista mu, alfenta. O composto agonista delta pode compreender um composto da fórmula (I), em que as variáveis de Ar, G, R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^ e R^ 7^ são aqui descritas na descrição.
BR9714739-7A 1997-07-03 1997-10-01 Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu BR9714739A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/887,312 US5985880A (en) 1996-06-05 1997-07-03 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
PCT/US1997/017852 WO1999001033A1 (en) 1997-07-03 1997-10-01 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds

Publications (1)

Publication Number Publication Date
BR9714739A true BR9714739A (pt) 2000-07-25

Family

ID=25390891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714739-7A BR9714739A (pt) 1997-07-03 1997-10-01 Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu

Country Status (23)

Country Link
US (5) US5985880A (pt)
EP (1) EP1003373B1 (pt)
JP (1) JP2002502432A (pt)
KR (1) KR20010014279A (pt)
CN (1) CN1165308C (pt)
AT (1) ATE259226T1 (pt)
AU (1) AU756120B2 (pt)
BR (1) BR9714739A (pt)
CA (1) CA2294924C (pt)
CZ (1) CZ9904694A3 (pt)
DE (1) DE69727593D1 (pt)
HU (1) HUP0003842A3 (pt)
IL (1) IL133600A0 (pt)
IS (1) IS5309A (pt)
NO (1) NO996310L (pt)
NZ (1) NZ501817A (pt)
PL (1) PL337578A1 (pt)
RU (1) RU2201231C2 (pt)
SI (1) SI20245A (pt)
SK (1) SK185399A3 (pt)
TR (1) TR199903324T2 (pt)
TW (1) TW513426B (pt)
WO (1) WO1999001033A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985880A (en) * 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
WO2001043726A1 (en) * 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
WO2001089535A1 (en) 2000-05-24 2001-11-29 University Of Maryland Biotechnology Institute Method for introducing and expressing genes in animal cells, and bacterial blebs for use in same
US7229994B2 (en) 2001-05-18 2007-06-12 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
RU2309153C2 (ru) * 2001-09-25 2007-10-27 Маунт Кук Байосайенсиз, Инк. Энантиомерно чистый опиоидный диарилметилпиперазин и способы его применения
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
WO2003037342A1 (en) * 2001-10-29 2003-05-08 Ardent Pharmaceuticals, Inc. Method of treating depression with delta receptor agonist compounds
EP1469850B1 (en) 2002-01-02 2013-01-02 Versi Group, LLC Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US8476280B2 (en) * 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
EP1567490B1 (en) * 2002-12-04 2011-10-05 Virginia Commonwealth University Anti-sickling agents
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7119208B2 (en) * 2003-12-03 2006-10-10 Virginia Commonwealth University Anti-sickling agents
DK1781631T3 (da) 2004-08-02 2012-05-14 Astrazeneca Ab Diarylmethylpiperazinderivater, præparater dermed og anvendelser deraf
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CA2643677C (en) * 2005-04-14 2015-06-23 Mount Cook Biosciences, Inc. Compositions of novel opioid compounds and method of use thereof
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8883817B2 (en) * 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
TWI522101B (zh) * 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3800177B1 (en) 2015-12-22 2025-01-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
WO2018204163A1 (en) 2017-04-30 2018-11-08 Versi Group, Llc An opioid for use to reduce and/or treat drug addiction
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) * 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2630435A (en) * 1948-09-09 1953-03-03 Burroughs Wellcome Co N-benzohydryl-n-methyl piperazines and process of preparing same
US4065573A (en) * 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
US4167574A (en) * 1978-03-13 1979-09-11 Janssen Pharmaceutica, N.V. N-phenyl-N-(4-piperidinyl)amides
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
GB8320701D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
ATE110057T1 (de) * 1987-04-16 1994-09-15 Lilly Co Eli Piperidine als opioid-antagoniste.
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
HUT59377A (en) * 1989-06-19 1992-05-28 Wellcome Found Process for producing drugs containing new aromatic rings
EP0415693A1 (en) * 1989-08-28 1991-03-06 Arizona Technology Development Corporation Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence
EP0458160A3 (en) 1990-05-25 1992-03-18 Sociedad Espanola De Especialidades Farmaco-Terapeuticas, S.A. Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
HU219332B (hu) * 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
RU2133744C1 (ru) * 1993-07-30 1999-07-27 Дельта Фармасьютикалз, Инк. Пиперазиновые соединения
IT1270612B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Derivati eterociclo-condensatori di morfinoidi
US5753516A (en) * 1995-02-03 1998-05-19 Heagy; Wyrta E. Screening method for ligands of the EBI-1 receptor
IT1275433B (it) * 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
IT1277597B1 (it) * 1995-09-15 1997-11-11 Smithkline Beecham Spa Derivati di diarilalchenilammina
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds

Also Published As

Publication number Publication date
US20050255151A1 (en) 2005-11-17
EP1003373A4 (en) 2000-09-20
EP1003373A1 (en) 2000-05-31
CZ9904694A3 (cs) 2002-03-13
HUP0003842A3 (en) 2001-12-28
US5985880A (en) 1999-11-16
SK185399A3 (en) 2001-08-06
DE69727593D1 (de) 2004-03-18
WO1999001033A1 (en) 1999-01-14
CA2294924C (en) 2010-12-21
CA2294924A1 (en) 1999-01-14
NO996310D0 (no) 1999-12-17
CN1165308C (zh) 2004-09-08
RU2201231C2 (ru) 2003-03-27
IL133600A0 (en) 2001-04-30
TR199903324T2 (xx) 2000-09-21
IS5309A (is) 1999-12-17
NZ501817A (en) 2002-02-01
ATE259226T1 (de) 2004-02-15
AU4806697A (en) 1999-01-25
NO996310L (no) 2000-02-22
TW513426B (en) 2002-12-11
HUP0003842A1 (hu) 2001-04-28
US20020111359A1 (en) 2002-08-15
PL337578A1 (en) 2000-08-28
SI20245A (sl) 2000-12-31
US6919350B2 (en) 2005-07-19
US20080193383A1 (en) 2008-08-14
CN1262600A (zh) 2000-08-09
EP1003373B1 (en) 2004-02-11
AU756120B2 (en) 2003-01-02
KR20010014279A (ko) 2001-02-26
US6300332B1 (en) 2001-10-09
JP2002502432A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
NO996310D0 (no) Sammensetninger og fremgangsmåter for å redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser
BR9912508A (pt) Métodos e composições transdérmicas para alìvio da dor
BR9808281A (pt) Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
FR2714378B1 (fr) Dérivés de l&#39;indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
ES2189804T3 (es) Composicion farmaceutica estabilizada que contiene bupropion.
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
BR9201854A (pt) Composto derivado de pridazinas,processo para sua preparacao,e,composicao farmaceutica
KR930003912A (ko) 울혈성 심장 마비 치료법
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
BR0309933A (pt) (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetraidrofurilc arbonil)-4-piperidinil-metil]-4-piperidinil] benzamida, processo para sua preparação, composição farmacêutica contendo o mesmo e intermediários obtidos desta forma
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BRPI0417902A (pt) piperazinas úteis no tratamento da dor
PT92649A (pt) Processo para a preparacao do 4-fluoro-2-&lt; { (4-metoxi-2-piridinil)-metil}-sulfinil&gt;-1h-benzimidazol e de composicoes farmaceuticas que o contem
EP0844241A4 (en) INHIBITOR OF DEPENDENCE / RESISTANCE TO NARCOTIC ANALGESICS
BRPI0407529A (pt) uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática
PT896821E (pt) Uma nova composicao farmaceutica para inalacao que contem cr 2039 (andolast)
BR9713087A (pt) Composição farmacêutica estabilizada, utilização e processo para preparar a mesma, e, utilização de ácido metanossulfÈnico ou ácido clorìdrico
PT90614A (pt) Processo para a preparacao de tienil-piperazinonas e de composicoes farmaceuticas que os contem
KR870008885A (ko) 2-알콕시-n(1-아자비사이클로 [2,2,2] 옥트-3-일) 벤즈 아미드-n-옥사이드를 사용하여 구토증을 억제하는 방법
BR9809524A (pt) Mistura fungicida, processo para controlar fungos nocivos, uso de um composto, e, composição
PT89350A (pt) Processo para a preparacao de uma combinacao sinergistica de inibidores de descarboxilase e de l-dopa e de composicoes farmaceuticas que a contem

Legal Events

Date Code Title Description
TC Change of name
TE Change of address
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/40, A61K 31/445, A61K 31/55

Ipc: A61K 31/40 (2007.10), A61K 31/445 (2007.10), A61K

B25C Requirement related to requested transfer of rights

Owner name: ARDENT PHARMACEUTICALS, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020070126804/RJ DE 11/09/2007, APRESENTE A DEVIDA LEGALIZACAO CONSULAR.

B25A Requested transfer of rights approved

Owner name: MOUNT COOK BIOSCIENCES, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE INFRINGE OS ARTIGOS 8O E 13 DA LPI